Claims
- 1. An implantable permselective device for use in cell therapy comprising:
- (a) a core comprising living cells that are capable of secreting a selected biologically active product or of providing a selected biological function; and
- (b) an external jacket surrounding said core, said jacket comprising a biocompatible material substantially free of said cells, said jacket having a nominal molecular weight cutoff greater than about 440 kD; said core and said jacket forming a macrocapsule, which device is substantially non-immunoisolatory.
- 2. The permselective device of claim 1 wherein said core additionally comprises a hydrogel matrix, said living cells being immobilized by said matrix.
- 3. The permselective device of claim 1 wherein said biocompatible material is comprised of hydrogels.
- 4. The permselective device of claim 2 wherein said core and said biocompatible materials are comprised of the same hydrogel.
- 5. The permselective device of claim 1 wherein said biocompatible material comprises alginate cross-linked with a multivalent ion.
- 6. The permselective device of claim 1 wherein said biocompatible material comprises a thermoplastic membrane.
- 7. The permselective device of claim 1 wherein the said nominal molecular weight cutoff is between about 1,000 to about 3,000 kD.
- 8. The permselective device of claim 1 wherein said external jacket has a nominal molecular weight cutoff below the molecular weight of detrimental viruses which may be shed from said living cells.
- 9. The permselective device of claim 1 wherein said living cells have been genetically modified with a virus, and said nominal molecular weight cutoff is below the molecular weight of said virus.
- 10. The permselective device of claim 9 wherein said external jacket has a viral retentivity value of less than about 10.sup.2.
- 11. The permselective device of claim 1 further comprising:
- (c) a tether for the retrieval of said device.
- 12. The permselective device of claim 1 wherein said core additionally comprises immunoisolatory devices in which said living cells are encapsulated.
- 13. The permselective device of claim 12 wherein said immunoisolatory devices are selected from the group consisting of microspheres and alginate noodles.
- 14. An implantable device for providing a therapeutically useful product to a recipient, the device comprising:
- (a) a core comprising a polymeric implant that is capable of secreting a selected therapeutically useful product, and
- (b) an external jacket surrounding said core formed of a biocompatible material, said jacket having a nominal molecular weight cutoff greater than about 440 kD;
- said core and said jacket forming a macrocapsule, which macrocapsule is substantially non-immunoisolatory.
- 15. A method of cell therapy comprising implanting a permselective device into the body of a recipient, said device comprising:
- (a) a core comprising living cells that are capable of secreting a selected biologically active product or of providing a selected biological function; and
- (b) an external jacket surrounding said core, said jacket comprising a biocompatible material substantially free of said cells, said jacket having a nominal molecular weight cutoff greater than about 440 kD;
- said core and said jacket forming a macrocapsule, which macrocapsule is substantially non-immunoisolatory.
- 16. The method of claim 15 wherein said external jacket has a molecular weight cutoff below the molecular weight of detrimental viruses which may be shed from said living cells.
- 17. The method of claim 15 wherein said living cells have been genetically modified with a virus, and said nominal molecular weight cutoff is below the molecular weight of said virus.
- 18. The method of claim 17 wherein said external jacket has a Viral retentivity value of less than about 10.sup.2.
- 19. The method of claim 15 wherein said permselective device further comprises:
- (c) a tether for the retrieval of said macrocapsule, and said method comprises the additional step of retrieving said macrocapsule at the termination of said therapy.
CROSS-REFERENCES TO RELATED APPLICATIONS
This application is a national stage filing under 35USC371 of PCT/US93/11232 which claims priority to U.S. Ser. No. 07/975,354 now abandoned , which is a continuation-in-part of copending PCT application U.S. Pat. No. 92103327, filed Apr. 22, 1992, which claims priority to U.S. Ser. No. 07/692,403, filed Apr. 25, 1991. The contents of the related applications are hereby expressly incorporated by reference.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US93/11232 |
11/16/1993 |
|
|
8/14/1995 |
8/14/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO94/10950 |
5/26/1994 |
|
|
US Referenced Citations (6)
Non-Patent Literature Citations (2)
Entry |
Stanier, et al., "The Bacterial Virus" General Microbiology 373-374 (1976). |
Freshney, "Virus Preparation and Assay" Culture of Animal Cells: A Manual of Basic Technique (A John Wiley & Sons, Inc.: New York) pp. 402-403. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US92/03327 |
Apr 1992 |
|